Verastem, Inc. (2VSA.F)
EUR 4.32
(-2.26%)
EUR 4.32
(-2.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -36.35 Million USD | 24.06% |
| 2022 | -47.86 Million USD | 51.15% |
| 2021 | -97.99 Million USD | -116.6% |
| 2020 | -45.24 Million USD | -170.67% |
| 2019 | 64.01 Million USD | 780.03% |
| 2018 | -9.41 Million USD | 86.02% |
| 2017 | -67.34 Million USD | -108.19% |
| 2016 | -32.34 Million USD | 70.66% |
| 2015 | -110.25 Million USD | -225.24% |
| 2014 | -33.9 Million USD | -79.47% |
| 2013 | -18.88 Million USD | -87.09% |
| 2012 | -10.09 Million USD | 51.82% |
| 2011 | -20.95 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -39.03 Million USD | -7.37% |
| 2024 Q2 | -41.5 Million USD | -6.34% |
| 2023 Q1 | -54.32 Million USD | -13.48% |
| 2023 Q3 | -52.95 Million USD | 62.34% |
| 2023 Q4 | -36.35 Million USD | 31.35% |
| 2023 Q2 | -140.59 Million USD | -158.82% |
| 2023 FY | -36.35 Million USD | 24.06% |
| 2022 Q2 | -62.06 Million USD | -218.27% |
| 2022 Q4 | -47.86 Million USD | 6.24% |
| 2022 FY | -47.86 Million USD | 51.15% |
| 2022 Q1 | -19.5 Million USD | 80.1% |
| 2022 Q3 | -51.05 Million USD | 17.74% |
| 2021 Q2 | -1.42 Million USD | 88.62% |
| 2021 FY | -97.99 Million USD | -116.6% |
| 2021 Q3 | -20.99 Million USD | -1377.13% |
| 2021 Q4 | -97.99 Million USD | -366.85% |
| 2021 Q1 | -12.48 Million USD | 72.41% |
| 2020 Q2 | -65.72 Million USD | 13.52% |
| 2020 Q1 | -76 Million USD | -218.72% |
| 2020 Q4 | -45.24 Million USD | 58.99% |
| 2020 FY | -45.24 Million USD | -170.67% |
| 2020 Q3 | -110.31 Million USD | -67.84% |
| 2019 Q2 | 24.74 Million USD | -28.19% |
| 2019 Q1 | 34.45 Million USD | 466.04% |
| 2019 FY | 64.01 Million USD | 780.03% |
| 2019 Q4 | 64.01 Million USD | 74.14% |
| 2019 Q3 | 36.76 Million USD | 48.57% |
| 2018 Q3 | -105.66 Million USD | 26.51% |
| 2018 Q2 | -143.78 Million USD | -191.65% |
| 2018 Q1 | -49.3 Million USD | 26.8% |
| 2018 FY | -9.41 Million USD | 86.02% |
| 2018 Q4 | -9.41 Million USD | 91.09% |
| 2017 Q4 | -67.34 Million USD | -37.63% |
| 2017 Q3 | -48.93 Million USD | -93.5% |
| 2017 Q2 | -25.29 Million USD | 2.47% |
| 2017 FY | -67.34 Million USD | -108.19% |
| 2017 Q1 | -25.93 Million USD | 19.84% |
| 2016 Q2 | -39.56 Million USD | -161.2% |
| 2016 Q4 | -32.34 Million USD | 13.21% |
| 2016 FY | -32.34 Million USD | 70.66% |
| 2016 Q1 | -15.14 Million USD | 39.1% |
| 2016 Q3 | -37.27 Million USD | 5.79% |
| 2015 FY | -110.25 Million USD | -225.24% |
| 2015 Q4 | -24.87 Million USD | -25.41% |
| 2015 Q3 | -19.83 Million USD | 43.62% |
| 2015 Q2 | -35.17 Million USD | -16.75% |
| 2015 Q1 | -30.12 Million USD | 11.14% |
| 2014 Q3 | -20.55 Million USD | 8.19% |
| 2014 Q1 | -13.24 Million USD | 29.89% |
| 2014 FY | -33.9 Million USD | -79.47% |
| 2014 Q2 | -22.39 Million USD | -69.07% |
| 2014 Q4 | -33.9 Million USD | -64.91% |
| 2013 Q3 | -22.64 Million USD | -63.11% |
| 2013 Q1 | -28.24 Million USD | -179.76% |
| 2013 FY | -18.88 Million USD | -87.09% |
| 2013 Q4 | -18.88 Million USD | 16.57% |
| 2013 Q2 | -13.88 Million USD | 50.86% |
| 2012 Q3 | -11.12 Million USD | 29.36% |
| 2012 Q4 | -10.09 Million USD | 9.26% |
| 2012 Q2 | -15.75 Million USD | 38.16% |
| 2012 Q1 | -25.47 Million USD | -21.55% |
| 2012 FY | -10.09 Million USD | 51.82% |
| 2011 Q4 | -20.95 Million USD | 66.11% |
| 2011 FY | -20.95 Million USD | 0.0% |
| 2011 Q3 | -61.82 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 99.682% |
| CureVac N.V. | -360.92 Million EUR | 89.928% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 106.363% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 106.363% |
| BRAIN Biotech AG | -693 Thousand EUR | -5145.599% |
| Formycon AG | 2.45 Million EUR | 1583.15% |
| Heidelberg Pharma AG | -37.6 Million EUR | 3.339% |
| Medigene AG | -5.72 Million EUR | -535.08% |